CSPC Pharma teases big bucks deals after earnings miss
The Chinese drug giant revealed it was in talks with three parties to license its products for up to $5 billion in potential fees, a day after it delivered lackluster…
Sinotau aims to become Hong Kong’s ‘first nuclear-medicine stock’
The company is China’s first to obtain approval for its innovative radiopharmaceuticals Key Takeaways: Sinotau has filed to list in Hong Kong, offering up two commercialized products and a net…
3SBio hits the big time with $6 billion cancer drug deal
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega…
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
Shares of Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) jumped in their Hong Kong trading debut on Friday, as the leading drug maker’s new IPO complemented its existing listing in…
Will Trump’s drug order put the brakes on China’s overseas pharma drive?
The U.S. president has promised to reduce prescription drug prices by 30% to 80% for Americans, insisting they are entitled to prices paid in other developed countries Key Takeaways: Pharma…
Estenova aims to become a big name in medical aesthetics
The Chinese developer of anti-wrinkle fillers is seeking a cash injection from a Hong Kong share listing to bring its plumping products to the market Key Takeaways: The biotech made…
RNA drug developer Ribo Life targets fresh funding channel
The biopharma firm has filed for a Hong Kong IPO after already completing eight financing rounds to support its research into cutting-edge nucleotide drugs Key Takeaways: As a pioneer in…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
